Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating

Caris Life Sciences, Inc. (NASDAQ:CAI) is among the 11 Newly-Listed NASDAQ Stocks to Buy Now.

On February 17, 2026, Baird initiated coverage of Caris Life Sciences, Inc. (NASDAQ:CAI) with an Outperform rating and a $26 price target. Baird described Caris Life Sciences, Inc. (NASDAQ:CAI) as a commercial-stage precision oncology company focused on comprehensive molecular information and machine learning algorithms. While Baird sees some uncertainty around pipeline offerings and 2026 consensus estimates, Baird believes the recent stock selloff has created an attractive entry point.

In January, Caris Life Sciences, Inc. (NASDAQ:CAI) reported fourth-quarter revenue of $281M, compared with the $204.31M consensus estimate. The company completed approximately 52,700 clinical therapy selection cases, up about 20%, including roughly 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.

For FY25, Caris Life Sciences, Inc. (NASDAQ:CAI) sees revenue of $800M versus the $723.42M consensus estimate and completed approximately 199,300 clinical therapy selection cases, an increase of 22%, consisting of about 170,300 MI Profile cases and approximately 29,000 Caris Assure cases.

Caris Life Sciences, Inc. (NASDAQ:CAI) is an artificial intelligence TechBio company that provides molecular profiling services and develops solutions using molecular information and machine learning algorithms in the United States and internationally.

While we acknowledge the potential of CAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 12 Best Tech Stocks that Beat Earnings Estimates.

Disclosure: None. Follow Insider Monkey on Google News.